StockData

Amylyx Pharmaceuticals vs Wave Life Sciences

AMLX and WVE side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How AMLX and WVE compare

Amylyx Pharmaceuticals is the larger company, worth 5.5 times as much as Wave Life Sciences ($3.1B against $566M).

Wave Life Sciences scores higher on the StockData Score (10 against 6 for Amylyx Pharmaceuticals), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricAMLXWVE
Size and price
Market cap$3.1B$566M
Share price$27.80$2.87
Change, 1 year124%−57.0%
Change, 5 years171%−28.1%
Beta (5Y)0.521.84
Employees136317
StockData Score
Total score610 (better)
Valuation score03 (better)
Growth score01 (better)
Performance score01 (better)
Health score6 (better)5
Dividend score00
Valuation
P/S–8.0×
P/B13.0×1.4× (better)
FCF yield–−36.8%
Fair value–$5.23
Margin of safety–45.1%
Growth
Revenue growth, 5Y average–16.3%
Profitability
Operating margin–−321%
Net margin–−297%
FCF margin–−294%
Return on equity−74.7% (better)−80.0%
Financial health
Debt / equity0.000.00
Current ratio12.12 (better)8.38
Altman Z-score67.80 (better)−1.27
Piotroski F-score4 (better)3
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions104%92.6%
Held by insiders7.8%23.1%
Insider net buying, 12 months−$17.2M$66.5M (better)
Superinvestors holding–1
Short interest, % of float12.5%13.6%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.